NLC

NLC, based in Amsterdam, The Netherlands, stands as a prominent European healthtech venture builder. Established in 2015, the firm distinguishes itself by actively sourcing and transforming science-based healthtech inventions into viable companies, rather than merely investing in existing startups. Their unique model involves identifying promising intellectual property from academic institutions and medical centers worldwide, and then building dedicated ventures around these innovations, providing the necessary capital, team, and operational support from inception. This hands-on approach aims to de-risk early-stage technologies and accelerate their path to market.

The core of NLC's strategy lies in its comprehensive venture building program. They assemble dedicated teams, develop business strategies, and provide initial seed capital to these newly formed entities. This initial capital injection, which can range from approximately $500,000 to $2,000,000 USD, is critical for validating the technology, developing prototypes, and achieving early milestones. Beyond the financial investment, NLC offers extensive in-kind support, including access to a vast network of industry experts, legal and regulatory guidance, and operational infrastructure, significantly reducing the typical challenges faced by nascent healthtech companies.

NLC has rapidly scaled its operations to become one of the largest healthtech venture builders globally. To date, the firm has successfully built over 140 ventures, demonstrating a remarkable capacity for translating scientific breakthroughs into commercial enterprises. These NLC-built companies have collectively attracted more than €600 million (approximately $650 million USD) in follow-on funding from a diverse range of institutional investors, validating the potential of their portfolio and the efficacy of their venture building model. NLC's overarching vision is to address critical healthcare needs by systematically bringing impactful healthtech innovations to patients worldwide, fostering a robust ecosystem for medical advancements.